For the quarter ending 2026-03-31, CCCC made $6,152K in revenue. -$25,501K in net income. Net profit margin of -414.52%.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Revenue from collaboration agreements | 6,152 | 11,016 | 11,230 | 6,463 |
| Impairment of long-lived assets | - | - | 10,733 | - |
| Restructuring | - | - | 0 | 0 |
| Research and development | 24,606 | 24,982 | 25,989 | 26,197 |
| General and administrative | 9,331 | 9,179 | 8,920 | 8,767 |
| Impairment loss on right-of-use asset | - | 0* | - | - |
| Restructuring | - | 0* | - | - |
| Total operating expenses | 33,937 | 34,161 | 45,642 | 34,964 |
| Loss from operations | -27,785 | -23,145 | -34,412 | -28,501 |
| Interest and other income, net | 2,656 | 2,780 | 2,246 | 2,481 |
| Total other income, net | 2,656 | 2,780 | 2,246 | 2,481 |
| Loss before income taxes | - | -20,365 | -32,166 | -26,020 |
| Income tax expense | - | 121 | - | - |
| Net loss | -25,129 | -20,486 | -32,166 | -26,020 |
| Unrealized (gain) loss on marketable securities | - | -37 | - | -73 |
| Unrealized loss on marketable securities | -372 | - | 117 | - |
| Comprehensive loss | -25,501 | -20,523 | -32,049 | -26,093 |
| Basic EPS | -0.2 | -0.175 | -0.44 | -0.37 |
| Diluted EPS | -0.2 | -0.175 | -0.44 | -0.37 |
| Basic Average Shares | 126,074,555 | 117,175,738 | 72,563,311 | 71,005,743 |
| Diluted Average Shares | 126,074,555 | 117,175,738 | 72,563,311 | 71,005,743 |
C4 Therapeutics, Inc. (CCCC)
C4 Therapeutics, Inc. (CCCC)